Panel recommends FDA restrict MRI scan drugs
An advisory panel has “recommended Tuesday that the Food and Drug Administration effectively ban, for patients with severe kidney disease, the use of two drugs used to create high-contrast images on magnetic resonance imaging (MRI) scans.” ProPublica’s Jeff Gerth has been reporting on the issue for some time and offers some valuable background on the topic.
The drugs in question are GE’s Omniscan and Covidien’s Optimark. Bayer’s Magnevist, the category’s market leader, escaped the most serious censure, but all three agents have been linked to nephrogenic systemic fibrosis, a rare but very serious disease.
Comments
One Comment on Panel recommends FDA restrict MRI scan drugs
-
GE uses UK libel law to silence Danish researcher : Covering Health on
Tue, 22nd Dec 2009 9:13 am
[...] Jeff Gerth, who has been all over the Omniscan story for a while now, reports in The Sunday Times (and on ProPublica) on the lawsuit and the science, economics and [...]
Please read our blog commenting policies.
-
Join us in Atlanta
for Health Journalism 2012
Fellowship applications
due Feb. 27
New at HealthJournalism.org
- Data gives depth to investigation of patient safety
- What reporters should know about Alzheimer’s and related dementias
- Apply for fellowships to attend Health Journalism 2012
- AHCJ asks Supreme Court to permit broadcast of arguments in health reform case
- Tips for print, online journalists to embrace broadcast opportunities
- Numbers reveal how often, or how rarely, states check doctors’ disciplinary records
- How I did it: Falsified charts in nursing homes linked to patient care
- Access Denied: Looking at a lack of health care availability
- Transparency & medical errors: Public reporting of patient harm is a potent force
